Amylyx Pharmaceuticals vs Septerna
AMLX and SEPN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMLX and SEPN compare
Amylyx Pharmaceuticals is the larger company, worth 1.7 times as much as Septerna ($3.3B against $2.0B).
Septerna scores higher on the StockData Score (8 against 7 for Amylyx Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMLX | SEPN |
|---|---|---|
| Size and price | ||
| Market cap | $3.3B | $2.0B |
| Share price | $29.86 | $41.86 |
| Change, 1 year | 135% | 118% |
| Change, 5 years | 178% | – |
| Beta (5Y) | 1.15 | 1.82 |
| Employees | 136 | 130 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 20.3× |
| P/B | 4.4× (better) | 4.6× |
| FCF yield | – | −4.0% |
| Fair value | – | $15.01 |
| Margin of safety | – | −179% |
| Growth | ||
| Revenue growth (TTM) | – | 337% |
| Profitability | ||
| Operating margin | – | −76.2% |
| Net margin | – | −61.3% |
| FCF margin | – | −80.6% |
| Return on equity | −30.1% | −14.4% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 26.81 (better) | 4.84 |
| Altman Z-score | 59.22 (better) | 6.18 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 104% | 102% |
| Held by insiders | 8.0% | 28.1% |
| Insider net buying, 12 months | −$10.0M (better) | −$76.1M |
| Short interest, % of float | 12.5% | 10.0% |
Go deeper
- AMLX stock overview
- AMLX income statement
- AMLX valuation and score
- SEPN stock overview
- SEPN income statement
- SEPN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.